Treatment of yellow scorpion (Leiurus quinquestriatus) sting: A case report
Lt Col Eric A. Shalita, USAF, BSC, FAPhA; Maj Ryan D. Wells, USAF, MC, MD, FAAEM, FACEP
J Am Pharm Assoc (2003) 2007;47:616-619. doi:10.1331/JAPhA.2007.07051


Objectives  To report the treatment given to a 26-year-old Air Force medic who was stung twice by a yellow scorpion (Leiurus quinquestriatus) while stationed in Iraq and to describe the problems and issues related to the use of the scorpion antivenin.

Patient case  The patient presented 2 hours after envenomation to the local military treatment facility, where she was minimally symptomatic initially. Shortness of breath and anxiety developed, and the patient was sedated, intubated, and evacuated to a large Air Force medical facility for more advanced care. Vasopressor support was required during flight. At the medical facility, antivenin was administered, and the patient's cardiac condition was stabilized with norepinephrine drip, mild hydration, and vasopressor support. A second dose of antivenin diluted in sodium chloride and further pressor support were required. ST-segment depression eventually resolved, and the patient was gradually taken off norepinephrine and extubated. She recovered fully within 2 weeks and returned to active duty.

Discussion  Because the antivenin used is not licensed by the Food and Drug Administration, informed consent was needed; however, it could not be obtained because the patient was unconscious, intubated, and in a life-or-death situation. Antivenin selection is based on the species of scorpion and symptom severity; therefore, the scorpion should be, with great care, killed for identification. In the military setting, inventory control, storage, and accountability are vital issues surrounding antivenin use, and these are discussed in this article.

Conclusion  Immediate action and effective communication, along with timely antivenin administration and well-equipped intensive care facilities, were integral in saving the life of this victim of a yellow scorpion envenomation. All level 3 facilities in Southwest Asia must be familiar with ordering, administering, and documenting this antivenin because it is difficult to obtain and infrequently available.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.


Register for a FREE limited account to benefit from personalization features such as alerts.


 The scorpion files. Accessed at www.ub.ntnu.no/scorpion-files/l_quinquestriatus.php, Nov . 24,  2006.
Amitai Y. Clinical manifestations and management of scorpion envenomation.  Public Health Rev.  1998;26:257–63.[PubMed]
Shapira MY, Haviv YS, Sviri S. Second degree atrio-ventricular block and cardiotoxicity secondary to envenomation by the scorpion Leiurus quinquestriatus (‘yellow scorpion’): an indication for serotherapy? Hum Exp Toxicol.  1998;17:541–3[PubMed][CrossRef]
Kristal C, Shemesh IY, Mishal Y, Bourvin A. Cardiac failure following sting of yellow scorpion in an adult.  Harefuah.  1998;134:452–4, 502.[PubMed]
Sofer S, Shahak E, Slonim A, et al. Myocardial injury without heart failure following envenomation by the scorpion Leiurus quinquestriatus in children.  Toxicon.  1991;29:382–5.[PubMed]
Gueron M, Margulis G, Sofer S. Echocardiographic and radionuclide angiographic observations following scorpion envenomation by Leiurus quinqestriatus.  Toxicon.  1990;28:1005–9.[PubMed]
Ben-Abraham R, Eshel G, Winkler E. Triage for Leiurus quinquestriatus scorpion envenomation in children: is routine hospitalization necessary? Hum Exp Toxicol.  2000;19:663–6.[PubMed]
Cheng D, Dattaro JA, Yakobi R. Scorpion sting. Accessed at www.emedicine.com/med/topic2081.htm, Nov . 24,  2006.
 National Antivenom and Vaccine Production Center. Scorpion antivenom serum. Accessed at www.antivenom-center.com/products/Polyvalent/index.htm, Nov . 30,  2006.
 CENTCOM/MNC-I policy for antivenins lacking U.S. Food and Drug Administration approval. Generated by the US Central Command, Multi-National Coalition-Iraq Headquarters, Baghdad, Iraq, dated July 7, 2007, to establish the theater policy for the management, use, and reporting requirements of investigational antivenins.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content

Customize your page view by dragging & repositioning the boxes below.

Topic Collections
PubMed Articles
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints